LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

CEO and Board Appointment

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that Matthew (Matt) Sassone has agreed to join the Board as Chief Executive Officer. He will take up his appointment with effect from 15 June 2015, initially as director and Chief Executive Officer Designate, whilst he works with Dr Terry O'Brien, the current Chief Executive Officer, in respect of the handover of his duties.

Mr Sassone has a degree in biochemistry with microbiology, a diploma in management studies and a CIM diploma. He has over 18 years' experience in the medical industry having started his career in sales for Quintiles in 1996. Mr Sassone spent 12 years at Smiths Medical in various sales, marketing and business development roles achieving the role of Managing Director, Northern and Eastern Europe and Russia in 2010 where he had full P&L responsibility for 300 employees and £150m of revenue. In 2012 he moved to ArjoHuntleigh, a division of the Getinge Group, as Senior Vice President Global Marketing and he is currently Chief Marketing Officer of Maquet (turnover £1.1 billion in intensive care, surgery and anesthesia systems), also a division of Getinge. During his career Matt has been involved with products used in surgery and intensive care. His knowledge of the market for LiDCO's products and customers, coupled to a broad management and sales skill set, ideally positions him to execute on the Company's sales expansion into the UK and overseas.

Terry O'Brien (CEO and LiDCO's founder) will retire from his Board position and role as CEO of LiDCO following a period where he will work alongside Matt to ensure a smooth handover. Terry's retirement and Matt's appointment as CEO are expected to take place on the 17 August 2015.

Commenting, Theresa Wallis, Non-Executive Chairman of LiDCO, said:

"I am delighted to welcome Matt to the Board. He brings to the Board a wealth of UK and international medical devices sales and marketing experience which will help us to drive revenues as we execute on our strategy."

Terry O'Brien, Chief Executive Officer of LiDCO, commented:  "I will be leaving LiDCO in good hands with Matt's appointment as CEO. He has the right experience and skills to take LiDCO through the commercial growth stage of LiDCO's evolution. We are all excited to welcome him to LiDCO.

"The journey from a hospital bench technology to a global commercial opportunity has been realised. I would like to thank on behalf of myself and co-founder Dr David Band, all of our shareholders, employees, customers and partners for their considerable support which has taken us to this exciting stage."

Matt Sassone, future Chief Executive Officer of LiDCO, commented: "I am delighted to be joining LiDCO, it is an honour to be taking over from Terry and to lead the company in its next phase of growth"

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Mr Matthew Giovanni Sassone, age 39

Mr Sassone does not currently hold any ordinary shares in the Company. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response

· guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

*BISTM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.